User login
Supplement Editor:
Zobair M. Younossi, MD, MPH
Contents
Foreword
Zobair M. Younossi, MD, MPH
The evolving treatment of chronic hepatitis C: Where we stand a decade out
Sherif Saadeh, MD, and Gary L. Davis, MD
Initial treatment for chronic hepatitis C: Current therapies and their optimal dosing and duration
Keyur Patel, MD, and John G. McHutchison, MD
Retreatment of patients who do not respond to initial therapy for chronic hepatitis C
Mitchell L. Shiffman, MD
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Anemia, neutropenia, and thrombocytopenia
Janus P. Ong, MD, and Zobair M. Younossi, MD, MPH
The role of hematopoietic growth factors in special populations with chronic hepatitis C: Patients with HIV coinfection, end-stage renal disease, or liver transplantation
Stevan A. Gonzalez, MD, and Ira M. Jacobson, MD
Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C
Catherine C. Crone, MD; Geoffrey M. Gabriel, MD; and Thomas N. Wise, MD
The role of physician extenders in managing patients with chronic hepatitis C
Harpreet Gujral, RN, MSN, CRNP; Carla Viscomi, RN, BSN; and Rochelle Collantes, MD, MPH
Supplement Editor:
Zobair M. Younossi, MD, MPH
Contents
Foreword
Zobair M. Younossi, MD, MPH
The evolving treatment of chronic hepatitis C: Where we stand a decade out
Sherif Saadeh, MD, and Gary L. Davis, MD
Initial treatment for chronic hepatitis C: Current therapies and their optimal dosing and duration
Keyur Patel, MD, and John G. McHutchison, MD
Retreatment of patients who do not respond to initial therapy for chronic hepatitis C
Mitchell L. Shiffman, MD
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Anemia, neutropenia, and thrombocytopenia
Janus P. Ong, MD, and Zobair M. Younossi, MD, MPH
The role of hematopoietic growth factors in special populations with chronic hepatitis C: Patients with HIV coinfection, end-stage renal disease, or liver transplantation
Stevan A. Gonzalez, MD, and Ira M. Jacobson, MD
Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C
Catherine C. Crone, MD; Geoffrey M. Gabriel, MD; and Thomas N. Wise, MD
The role of physician extenders in managing patients with chronic hepatitis C
Harpreet Gujral, RN, MSN, CRNP; Carla Viscomi, RN, BSN; and Rochelle Collantes, MD, MPH
Supplement Editor:
Zobair M. Younossi, MD, MPH
Contents
Foreword
Zobair M. Younossi, MD, MPH
The evolving treatment of chronic hepatitis C: Where we stand a decade out
Sherif Saadeh, MD, and Gary L. Davis, MD
Initial treatment for chronic hepatitis C: Current therapies and their optimal dosing and duration
Keyur Patel, MD, and John G. McHutchison, MD
Retreatment of patients who do not respond to initial therapy for chronic hepatitis C
Mitchell L. Shiffman, MD
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Anemia, neutropenia, and thrombocytopenia
Janus P. Ong, MD, and Zobair M. Younossi, MD, MPH
The role of hematopoietic growth factors in special populations with chronic hepatitis C: Patients with HIV coinfection, end-stage renal disease, or liver transplantation
Stevan A. Gonzalez, MD, and Ira M. Jacobson, MD
Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C
Catherine C. Crone, MD; Geoffrey M. Gabriel, MD; and Thomas N. Wise, MD
The role of physician extenders in managing patients with chronic hepatitis C
Harpreet Gujral, RN, MSN, CRNP; Carla Viscomi, RN, BSN; and Rochelle Collantes, MD, MPH
